TOday’s Movers: GlaxoSmithKline PLC (LON:GSK) Stock Rating Reemphasized by Analysts at Liberum Capital; GBX 1350.00 Target Price Indicates -2.14% Potential

Share

GlaxoSmithKline PLC (LON:GSK) Rating Reaffirmed

London: In a note shared with investors and clients on Thursday morning, Liberum Capital reaffirmed their Hold rating on GlaxoSmithKline PLC (LON:GSK) shares. They now have a GBX 1350.00 target on the company. Liberum Capital’s target indicates a potential downside of -2.14% from the company’s last stock price.

From a total of 24 analysts covering GlaxoSmithKline PLC (LON:GSK) stock, 6 rate it a ”Buy”, 4 a “Sell”, and 20 a ”Hold”. This means that 20% of the ratings are positive. The highest target price is GBX 1800 while the lowest target price is GBX 1218. The mean of all analyst targets is GBX 1468 with a 6.66% above today’s (GBX 1378.04) stock price. GlaxoSmithKline PLC was the topic of 92 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. Morgan Stanley maintained shares on December 2 with “Equal-Weight” rating. JP Morgan maintained shares with “Neutral” rating and GBX 1370 target share price in a report from a November 17. Goldman Sachs maintained GSK stock in a recent report from November 24 with “Buy” rating. Berenberg maintained the rating on November 11. Berenberg has a “Hold” rating and a GBX 1590 price target on shares. Finally, Jefferies maintained the stock with “Hold” rating in a report issued on a November 18.

Approximately 399,183 shares of stock traded hands. GlaxoSmithKline plc (LON:GSK) has declined 9.01% since May 6, 2015 and is downtrending. It has underperformed by 8.73% the S&P500.

TOday’s Movers: GlaxoSmithKline PLC (LON:GSK) Stock Rating Reemphasized by Analysts at Liberum Capital; GBX 1350.00 Target Price Indicates -2.14% Potential

GlaxoSmithKline plc. is a healthcare firm that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company has a market cap of 66.82 billion GBP. The Firm operates in two divisions: Pharmaceuticals and Vaccines, and Consumer Healthcare. It has 6.78 P/E ratio. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.

According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.” Get a free copy of the Zacks research report on GlaxoSmithKline plc (GSK).

COMMENTS: